A financial model is only as useful as what it measures, and the Tufts CSDD analysis quantifying RBQM’s return on investment was explicit about its own gap: it left out rework reduction, data integrity improvements, and inspection readiness entirely. In a video interview published by CluePoints, Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD argue those omissions may represent more value than what the model actually captured, even as the modeled figures already reached $13.8 million in net financial value for a single Phase III oncology trial.
That framing matters because sponsors tend to justify RBQM adoption on the costs the model does quantify: monitoring efficiencies, earlier signal detection, reduced site burden. Rework is harder to count. When a data query goes undetected late in a trial, the correction chain touches data management, clinical operations, medical writing, and sometimes regulatory affairs. Multiply that across a development program and the costs accumulate well before any inspection. De Viron and Dirks suggest that a cleaner upstream data record, produced by continuous statistical oversight rather than periodic monitoring visits, compresses that rework substantially, though they stop short of putting a dollar figure on it precisely because one has not yet been formally modeled.
Inspection readiness is the sharper edge of this argument. FDA’s April 2023 finalized guidance on risk-based monitoring positions RBQM not as an alternative to oversight but as a more systematic form of it, one regulators can trace and audit. A sponsor that has documented centralized statistical review throughout a trial arrives at an inspection with an auditable quality signal history rather than a collection of site visit reports. That is a structural advantage over traditional monitoring, not just an operational one.
Published ROI estimates across trial phases range from $3.2 million in Phase I to $18.9 million in Phase III, figures that still exclude the factors De Viron and Dirks raise. The practical implication for sponsors evaluating RBQM investment is that every internal analysis built on those modeled returns is a floor, not a ceiling. The next credible test of the full value case will be whether Tufts CSDD or another academic group attempts to formally quantify rework and inspection costs in a subsequent study.
Source link: https://cluepoints.com/the-unquantified-value-of-rbqm-reduced-rework-data-integrity-and-inspection-readiness/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
